Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

被引：0

作者：

Amoozgar, Behzad ^{[1
]}

Bangolo, Ayrton, I ^{[2
]}

Uesole, David H. ^{[3
,4
]}

Siegel, David S. ^{[5
,6
]}

Biran, Noa ^{[3
]}

Phull, Pooja ^{[3
]}

Donato, Michele L. ^{[7
]}

Parmar, Harsh ^{[3
]}

机构：

[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[2] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Edgewater, NJ USA

[3] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Div Multiple Myeloma, Hackensack, NJ USA

[4] Medstar GeorgetownMed Ctr, Lombardi Comprehens Canc Ctr, Washington, DC USA

[5] Hackensack Meridian Hlth, John Theurer Canc Ctr, Div Multiple Myeloma, Hackensack, NJ USA

[6] Ctr Discovery & Innovat, Hackensack, NJ USA

[7] Hackensack Meridian Hlth, John Theurer Canc Ctr, Stem Cell Transplantat & Cellular Therapy Program, Hackensack, NJ USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-211671

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2408 / 2409

页数：2

共 50 条

[1] Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
Merz, Maximilian
Albici, Anca-Maria
von Tresckow, Bastian
Rathje, Kristin
Fenk, Roland
Holderried, Tobias
Mueller, Fabian
Tovar, Natalia
Oliver-Caldes, Aina
Vucinic, Vladan
Kharboutli, Soraya
Baermann, Ben-Niklas
Ayuk, Francis
Platzbecker, Uwe
Stoelzel, Friedrich
Schub, Nathalie
Schmitz, Friederike
Fandrei, David
Born, Patrick
Khandanpour, Cyrus
Hanoun, Christine
Hoerster, Keven
Teichert, Marcel
Jeker, Barbara
Hoffmann, Michele
Kroeger, Nicolaus
de Larrea, Carlos Fernandez
Pabst, Thomas
Gagelmann, Nico
HEMASPHERE, 2025, 9 (01):
[2] A Real-World Comparison of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR-T Therapy: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma
Gill, Sarvarinder Kaur
Biran, Noa
Phull, Pooja
Vesole, David H.
Siegel, David S.
Parmar, Harsh
BLOOD, 2023, 142
[3] Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma
Davis, James
McGann, Mary
Shockley, Abigail
Hashmi, Hamza
EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (06) : 473 - 475
[4] Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study
Chang, Darryl
Habib, Alma
Uegel, Andrew
Struble, Emily
Shaikh, Hira
Strouse, Christopher
Green, Kimberly M.
Mushtaq, Muhammad Umair
Mahmoudjafari, Zahra
Hashmi, Hamza
Mcguirk, Joseph P.
Khan, Abdullah Mohammad
Abdallah, Al-Ola
Ahmed, Nausheen
Atrash, Shebli
Bhutani, Manisha
BLOOD, 2024, 144 : 2404 - 2405
[5] Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A with the Cartitude-1 Trial
Kamboj, Ishita
Chang, Darryl
Habib, Alma
Vegel, Andrew
Struble, Emily
Shaikh, Hira
Strouse, Christopher
Davis, James A.
Rashid, Aliya
Graf, Kevin
Green, Kimberly M.
Mushtaq, Muhammad Umair
Mahmoudjafari, Zahra
Hashmi, Hamza
Mcguirk, Joseph P.
Abdallah, Al-Ola
Atrash, Shebli
Khan, Abdullah Mohammad
Ahmed, Nausheen
BLOOD, 2024, 144 : 24112 - 24113
[6] A Comparison of Standard of Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR T-cell Therapy in Relapsed or Refractory Multiple Myeloma
Hansen, Doris
Peres, Lauren
Dima, Danai
Richards, Alicia
Shune, Leyla
Afrough, Aimaz
Midha, Shonali
Dhakal, Binod
Kocoglu, Mehmet H.
Ferreri, Christopher
Davis, James
Herr, Megan
Forsberg, Peter
Janakiram, Murali
Reshef, Ran
Sborov, Douglas W.
Khouri, Jack
Richard, Shambavi
Martin, Thomas
Lin, Yi
Patel, Krina
Sidana, Surbhi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S5 - S5
[7] Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis
OReilly, Maeve A.
Wilson, William
Burns, David
Kuhnl, Andrea
Seymour, Frances
Uttenthal, Ben
Besley, Caroline
Alajangi, Rajesh
Creasey, Thomas
Paneesha, Shankara
Elliot, Johnathon
Arias, Carlos Gonzalez
Iyengar, Sunil
Wilson, Matthew R.
Delaney, Alison
Rubio, Lourdes
Lambert, Jonathan
Begg, Khalil
Boyle, Stephen
Cheok, Kathleen P. L.
Collins, Graham P.
Roddie, Claire
Johnson, Rod
Sanderson, Robin
HEMASPHERE, 2024, 8 (06):
[8] Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Hansen, Doris K.
Sidana, Surbhi
Peres, Lauren C.
Leitzinger, Christelle Colin
Shune, Leyla
Shrewsbury, Alexandria
Gonzalez, Rebecca
Sborov, Douglas W.
Wagner, Charlotte
Dima, Danai
Hashmi, Hamza
Kocoglu, Mehmet H.
Atrash, Shebli
Simmons, Gary
Kalariya, Nilesh
Ferreri, Christopher
Afrough, Aimaz
Kansagra, Ankit
Voorhees, Peter
Baz, Rachid
Khouri, Jack
Alsina, Melissa
McGuirk, Joseph
Locke, Frederick L.
Patel, Krina K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (11) : 2087 - +
[9] KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Sundar Jagannath
Yi Lin
Hartmut Goldschmidt
Donna Reece
Ajay Nooka
Alicia Senin
Paula Rodriguez-Otero
Ray Powles
Kosei Matsue
Nina Shah
Larry D. Anderson
Matthew Streetly
Kimberly Wilson
Hoa Van Le
Arlene S. Swern
Amit Agarwal
David S. Siegel
Blood Cancer Journal, 11
[10] Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Sidana, Surbhi
Patel, Krina K.
Peres, Lauren C.
Bansal, Radhika
Kocoglu, Mehmet H.
Shune, Leyla
Atrash, Shebli
Smith, Kinaya
Midha, Shonali
Ferreri, Christopher
Dhakal, Binod
Dima, Danai
Costello, Patrick
Wagner, Charlotte
Reshef, Ran
Hosoya, Hitomi
Mikkilineni, Lekha
Atanackovic, Djordje
Chhabra, Saurabh
Parrondo, Ricardo
Nadeem, Omar
Mann, Hashim
Kalariya, Nilesh
Hovanky, Vanna
De Avila, Gabriel
Freeman, Ciara L.
Locke, Frederick L.
Alsina, Melissa
Wong, Sandy
Herr, Megan
Htut, Myo
Mcguirk, Joseph
Sborov, Douglas W.
Khouri, Jack
Martin, Thomas
Janakiram, Murali
Lin, Yi
Hansen, Doris K.
BLOOD, 2025, 145 (01) : 85 - 97

← 1 2 3 4 5 →